Eli Lilly and Company News - May 2026
Eli Lilly secures full PBM coverage for Zepbound, ending CVS exclusion
Eli Lilly secured coverage for obesity drugs Zepbound and Foundayo from all three major U.S. pharmacy benefit managers. CVS Caremark will add both medications...
Eli Lilly buys three biotechs for $4 billion, returning to vaccines
Eli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics, and Vaccine Company. The combined acquisitions total nearly $4 billion. This strategy...
Eli Lilly Achieves 28% Weight Loss in Trial, Rivaling Bariatric Surgery
Eli Lilly announced Thursday that its experimental obesity drug, retatrutide, met all primary and secondary endpoints in a pivotal Phase 3 trial. The...
Eli Lilly's first quarter 2026 revenue surged 56% on GLP-1 drug sales, leading to a raised full-year outlook.
Eli Lilly reported first-quarter revenue of $19.8 billion, a 56% increase year-over-year, with non-GAAP EPS growing 156% to $8.55. These results were driven by...